A new trading day began on Monday, with Atyr Pharma Inc (NASDAQ: ATYR) stock price down -4.17% from the previous day of trading, before settling in for the closing price of $0.71. ATYR’s price has ranged from $0.64 to $7.29 over the past 52 weeks.
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 34.28%. Meanwhile, its annual earnings per share averaged 2.49%. With a float of $95.56 million, this company’s outstanding shares have now reached $97.99 million.
Atyr Pharma Inc (ATYR) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Atyr Pharma Inc is 2.48%, while institutional ownership is 63.39%. The most recent insider transaction that took place on Oct 08 ’25, was worth 612,437. In this transaction Director of this company bought 682,001 shares at a rate of $0.90, taking the stock ownership to the 1,095,024 shares. Before that another transaction happened on Oct 09 ’25, when Company’s Director bought 317,999 for $0.94, making the entire transaction worth $299,364. This insider now owns 1,413,023 shares in total.
Atyr Pharma Inc (ATYR) Performance Highlights and Predictions
In its latest quarterly report, released on 12/31/2024, the company reported earnings of -0.18 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.15 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 2.49% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 14.14% during the next five years compared to 34.28% growth over the previous five years of trading.
Atyr Pharma Inc (NASDAQ: ATYR) Trading Performance Indicators
Here are Atyr Pharma Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 5.93. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 352.26.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.83, a number that is poised to hit -0.19 in the next quarter and is forecasted to reach -0.63 in one year’s time.
